Hepatitis C is a viral disease spread via blood that affects liver function and can lead to cirrhosis, cancer, and death. Risk factors include receiving blood transfusions or organ transplants before 1992, sharing intravenous drug needles or cocaine straws, engaging in rough sex, and receiving tattoos or piercings from unsterilized equipment. Unlike hepatitis A and B, there is no vaccine for hepatitis C. It can be cured through treatment, however, so it is important for those with risk factors to learn whether they have it.
The FDA today approved ombitasvir, paritaprevir, and ritonavir tablets copackaged with dasabuvir tablets to treat individuals with chronic hepatitis C virus genotype 1 infection, including patients with cirrhosis.
The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus and hepatitis C virus infection by focusing on the most vulnerable, high-risk patient populations.